ACUTE RHINOSINUSITIS: ACTUAL APPROACHES TO DIAGNOSIS AND TREATMENT

The incidence of upper respiratory tract acute pathologies is quite high and is 6.8 per 1,000  population in the autumn and winter period. According to the World Health Organization in Europe acute rhinosinusitis occur every seventh person per year, the disease is diagnosed in 16% of adults in the United States. There are 10000000 registered cases of acute rhinosinusitis each year in Russian Federation.

In recent years, acute sinusitis treatment, in addition to traditional antibacterial, anti-inflammatory, much attention is paid mucolytic drugs . Since 1994, new mucolytic drug sinupret has been registered for acute sinusitis treatment.

Analysis of the literature suggests  that Sinupret regulates the secretion and normalizes the viscosity of mucus; eliminates mukostasis; It acts on the mucous membrane decongestants and anti-inflammatory; restores drainage and ventilation of the paranasal sinuses; normalizes the protective function of the airway epithelium against endogenous and exogenous  damaging factors; It interrupts the vicious circle in inflammation of paranasal sinuses; antibiotic therapy improves the results.

Thus Sinupret drug can be recommended for the treatment of acute sinusitis in clinical practice. A number  of clinical trials have shown high efficacy, safety and convenience advantage of the drug in treating this highly prevalent and socially significant diseases.

1. ESCMID Sore Throat Guideline Group, Pelucchi C, Grigoryan L, Galeone C, Esposito S, Huovinen P, Little P, Verheij T. Guideline for the management of acute sore throat. Clinical Microbiology and Infection, 2012, 18(1): 1-28. DOI: 10.1111/j.1469-0691.2012.03766.x

2. Mustafa A, Debry Ch, Wiorowski M, Martin E, Gentine A. Treatment of acute mastoiditis: report of 31 cases over a ten year period. Revue de Laryngologie Otologie – Rhinologie, 2004, 125(3): 165-9.

3. Bisno L. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases in Clinical Practice, 2002, 35(2): 113-25. Doi 10.1097/00019048-200205000-00013.

4. Fokkens W, Lund V, Mullol J et al. European position paper on rhinosinusitis and nasal polyps 2012 (EP3OS). Rhinology, 2012, 50(23): 1-299.

5. Рязанцев С.В., Гаращенко Т.А., Карнеева О.В., Поляков Д.П., Свистушкин В.М., Кириченко И.М. Клинические рекомендации. Дифференциальная диагностика и лечение острого тонзиллофарингит. Москва, 2014. 22 с.

6. Otitis media: acute otitis media (AOM) and otitis media with effusion (OME). Victoria (BC): British Columbia Medical Services Commission, 2010: 7.

7. Wald ER, Applegate KE, Bordley C, Darrow DH, Glode MP, Marcy SM, Nelson CE, Rosenfeld RM, Shaikh N, Smith MJ, Williams PV, Weinberg ST. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics, 2013, 132(1): 262-80. doi 10.1542/peds.2013-1071.

8. University of Michigan Health System. Otitis media. Ann Arbor (MI): University of Michigan Health System, 2013: 12.

9. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann. Otol. Rhinol. Laryngol., 2004, 193(Suppl.): S3-S5.

10. Лечебно-диагностическая тактика при остром бактериальном синусите. Методические рекомендации Департамента здравоохранения Москвы. Сост. А.И. Крюков и др. М., 2002. 15 с.

11. Revai K, Dobbs LA, Nair S et al. Incidence of acute otitis media and sinusitis complicating upper respiratory tract infection: the effect of age. Pediatrics, 2007, 119(6): e1408-e1412.

12. Pleis JR, Lucas JW, Ward BW. Summary health statistics for US adults: National Health Interview Survey, 2008. Vital Health Stat, 2009, 10: 1-157.

13. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Российские практические рекомендации. М., 2014. 119 с.

14. Fokkens W, Lund V, Mullol J et al. European position paper on rhinosinusitis and nasal polyps 2012 (EP3OS). Rhinology, 2012, 50(23): 1-299.

15. Рязанцев С.В., Гаращенко Т.А., Гуров А. В. и др. Принципы этиопатогенетической терапии острых синуситов. Клинические рекомендации. Москва – Санкт-Петербург, 2014. 27 c.

16. Лечебно-диагностическая тактика при остром бактериальном синусите. Крюков А.И., Сединкин А.А. Рос. оторинолар., 2005, 4: 15-17.

17. Gill JM, Fleischut P, Haas S, Pellini B, Crawford A, Nash DB. Use of antibiotics for adult upper respiratory infections in outpatient settings: a national ambulatory network study. Fam Med, 2006, 38: 349-54.

18. American Academy of Pediatrics Subcommittee on Management of Sinusitis and Committee on Quality Improvement. Clinical practice guideline: management of sinusitis. Pediatrics, 2001, 108: 798-808.

19. http: //www.rlsnet.ru/mnn_index_id_1410.htm.

20. http: //www.rlsnet.ru/fg_index_id_38.htm.

21. http: //www.rlsnet.ru/tn_index_id_2923.htm.

22. Berghom K, Langer W, Marz R. Doppetolindstudie Sinupret Tropfer Tvs. Placebo auf Basis einer Therapie mit Antibiotikum und abschwellenden Nasentropfen bei akuter Sinusitis (N = 128) [unveroffentlichter Bericht]. Neumarkt: Bionorica GmbH, 1991.

23. Khan NA. Sinupret im HNO-Bereich. Therapiewoche, 1982, 32(13): 1811-1814.

24. Wahls M, Marz R. Randomisierte, Kontrollierte Doppelblindstudie Sinupret Tropfen vs. Mucosolvan Tropfen bei akuter und chronischer Sinusitis (N = 160) [unveroffentlichter Bericht]. Naumberg: Bionorica GmbH, 1990.

25. Richstein A, Mann W. Zur Behandlung der chronischen Sinusitis mit Sinupret. Ther d Gegenw, 1980, 119: 1055-1060.

26. Рязанцев С.В. Секретолитическая и секретомоторная терапия острых и хронических синуситов. Новости оторинолар. и логопатол., 1998, 4(16): 90-93.

27. Pape H-G, Simm K-J, Marz R. Doppelblindstudie Sinupret vs. Mucosolvan mit / ohne Nasentropfen bei akuter Sinusitis (N = 160) [unveroffentlichter Bericht]. Naumberg: Bionorica GmbH, 1991.